Although combination with epigenetic drugs and inhibitors of PD-1/PD-L1 showed promising results on cancer treatment, the mechanism for such increased efficacy remains elusive, and further clinical studies are needed for elucidation of the optimal treatment conditions for the patients. This evidence concerns the gene CD274 and cancer.